Thank you - and yes it was due to the pricing construct for both, so thanks for explaining it.
(also acknowledge common is probably more appropriate way to label it than me saying 'mainstream')
but I wonder, if it makes more sense commercially, there's nothing stopping them from pivoting from rare to common down the line right - or would there be? Obviously not great for sufferes of the rare diseases
with regards to patents, do these apply to the drug itself or the drug being used for a particular disorder?
eg could a strategy be... to focus on the rare diseases for now (perhaps an easier pathway to commercialisation) and then prove out common disorders in the background, to launch when parents expire on Retts, PHS, PMD etc
Or is this still thinking and doesn't really work?
- Forums
- ASX - By Stock
- NEU
- Share Price
Share Price, page-11178
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$15.76 |
Change
-0.180(1.13%) |
Mkt cap ! $2.027B |
Open | High | Low | Value | Volume |
$16.25 | $16.32 | $15.75 | $6.661M | 417.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 108 | $15.76 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.77 | 558 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 2095 | 15.760 |
11 | 2097 | 15.750 |
4 | 348 | 15.740 |
4 | 449 | 15.730 |
2 | 300 | 15.720 |
Price($) | Vol. | No. |
---|---|---|
15.770 | 204 | 8 |
15.780 | 1131 | 15 |
15.790 | 723 | 7 |
15.800 | 416 | 5 |
15.810 | 401 | 5 |
Last trade - 14.24pm 14/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |